[
  {
    "ts": null,
    "headline": "Medtronic PLC stock outperforms competitors despite losses on the day",
    "summary": "Medtronic PLC stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=9eaf1de16d31093f85a1d6ebe212f05d9e1849fd7ce61dce752de95ff32b1962",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626580,
      "headline": "Medtronic PLC stock outperforms competitors despite losses on the day",
      "id": 132148771,
      "image": "",
      "related": "MDT",
      "source": "MarketWatch",
      "summary": "Medtronic PLC stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=9eaf1de16d31093f85a1d6ebe212f05d9e1849fd7ce61dce752de95ff32b1962"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic price target lowered to $89 from $93 at Truist",
    "summary": "Truist lowered the firm’s price target on Medtronic (MDT) to $89 from $93 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets,",
    "url": "https://finnhub.io/api/news?id=def3e198e22227cc75dd455be3aa27a2ba71a1bc04600120bca358b734a65f6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611418,
      "headline": "Medtronic price target lowered to $89 from $93 at Truist",
      "id": 132054020,
      "image": "https://media.zenfs.com/en/tipranks_452/bbad1dd12cc6ba90ddd83aeee03f1aae",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Truist lowered the firm’s price target on Medtronic (MDT) to $89 from $93 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets,",
      "url": "https://finnhub.io/api/news?id=def3e198e22227cc75dd455be3aa27a2ba71a1bc04600120bca358b734a65f6e"
    }
  }
]